Biotech Is Black or White 🧬
It’s no secret that biotech is one of the riskiest industries for investors. That’s because developing novel therapeutics produces very black or white outcomes. In other words, you’re wrong or you’re right.
On the bright side: investors can make quick cash when companies successfully bring drugs to market (or make strides in doing so.) As mentioned in the Tale of the Tape, ChemoCentryx appreciated a double today after the FDA approved its new drug for vasculitis. ChemoCentryx develops drugs for inflammatory/autoimmune diseases and cancer. Back in May, an FDA advisory panel voted 10-8 in support of approving the drug that just got approved. The spike put ChemoCentryx back on the map:Â